Cargando…
Evaluation of nimotuzumab Fab(2) as an optical imaging agent in EGFR positive cancers
Molecular-targeted imaging probes can be used with a variety of imaging modalities to detect diseased tissues and guide their removal. EGFR is a useful biomarker for a variety of cancers, because it is expressed at high levels relative to normal tissues. Previously, we showed the anti-EGFR antibody...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328982/ https://www.ncbi.nlm.nih.gov/pubmed/37419997 http://dx.doi.org/10.1038/s41598-023-37873-9 |
_version_ | 1785069924650057728 |
---|---|
author | Bernhard, Wendy Barreto, Kris Toledo, Darien El-Sayed, Ayman Jett, Kimberly A. Casaco, Angel Fonge, Humphrey Geyer, C. Ronald |
author_facet | Bernhard, Wendy Barreto, Kris Toledo, Darien El-Sayed, Ayman Jett, Kimberly A. Casaco, Angel Fonge, Humphrey Geyer, C. Ronald |
author_sort | Bernhard, Wendy |
collection | PubMed |
description | Molecular-targeted imaging probes can be used with a variety of imaging modalities to detect diseased tissues and guide their removal. EGFR is a useful biomarker for a variety of cancers, because it is expressed at high levels relative to normal tissues. Previously, we showed the anti-EGFR antibody nimotuzumab can be used as a positron emission tomography and fluorescent imaging probe for EGFR positive cancers in mice. These imaging probes are currently in clinical trials for PET imaging and image-guided surgery, respectively. One issue with using antibody probes for imaging is their long circulation time and slow tissue penetration, which requires patients to wait a few days after injection before imaging or surgery, multiple visits and longer radiation exposure. Here, we generated a Fab(2) fragment of nimotuzumab, by pepsin digestion and labeled it with IRDye800CW to evaluate its optical imaging properties. The Fab(2) had faster tumor accumulation and clearance in mice relative to the nimotuzumab IgG. The fluorescent signal peaked at 2 h post injection and remained high until 6 h post injection. The properties of the Fab(2) allow a higher signal to background to be obtained in a shorter time frame, reducing the wait time for imaging after probe infusion. |
format | Online Article Text |
id | pubmed-10328982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-103289822023-07-09 Evaluation of nimotuzumab Fab(2) as an optical imaging agent in EGFR positive cancers Bernhard, Wendy Barreto, Kris Toledo, Darien El-Sayed, Ayman Jett, Kimberly A. Casaco, Angel Fonge, Humphrey Geyer, C. Ronald Sci Rep Article Molecular-targeted imaging probes can be used with a variety of imaging modalities to detect diseased tissues and guide their removal. EGFR is a useful biomarker for a variety of cancers, because it is expressed at high levels relative to normal tissues. Previously, we showed the anti-EGFR antibody nimotuzumab can be used as a positron emission tomography and fluorescent imaging probe for EGFR positive cancers in mice. These imaging probes are currently in clinical trials for PET imaging and image-guided surgery, respectively. One issue with using antibody probes for imaging is their long circulation time and slow tissue penetration, which requires patients to wait a few days after injection before imaging or surgery, multiple visits and longer radiation exposure. Here, we generated a Fab(2) fragment of nimotuzumab, by pepsin digestion and labeled it with IRDye800CW to evaluate its optical imaging properties. The Fab(2) had faster tumor accumulation and clearance in mice relative to the nimotuzumab IgG. The fluorescent signal peaked at 2 h post injection and remained high until 6 h post injection. The properties of the Fab(2) allow a higher signal to background to be obtained in a shorter time frame, reducing the wait time for imaging after probe infusion. Nature Publishing Group UK 2023-07-07 /pmc/articles/PMC10328982/ /pubmed/37419997 http://dx.doi.org/10.1038/s41598-023-37873-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Bernhard, Wendy Barreto, Kris Toledo, Darien El-Sayed, Ayman Jett, Kimberly A. Casaco, Angel Fonge, Humphrey Geyer, C. Ronald Evaluation of nimotuzumab Fab(2) as an optical imaging agent in EGFR positive cancers |
title | Evaluation of nimotuzumab Fab(2) as an optical imaging agent in EGFR positive cancers |
title_full | Evaluation of nimotuzumab Fab(2) as an optical imaging agent in EGFR positive cancers |
title_fullStr | Evaluation of nimotuzumab Fab(2) as an optical imaging agent in EGFR positive cancers |
title_full_unstemmed | Evaluation of nimotuzumab Fab(2) as an optical imaging agent in EGFR positive cancers |
title_short | Evaluation of nimotuzumab Fab(2) as an optical imaging agent in EGFR positive cancers |
title_sort | evaluation of nimotuzumab fab(2) as an optical imaging agent in egfr positive cancers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328982/ https://www.ncbi.nlm.nih.gov/pubmed/37419997 http://dx.doi.org/10.1038/s41598-023-37873-9 |
work_keys_str_mv | AT bernhardwendy evaluationofnimotuzumabfab2asanopticalimagingagentinegfrpositivecancers AT barretokris evaluationofnimotuzumabfab2asanopticalimagingagentinegfrpositivecancers AT toledodarien evaluationofnimotuzumabfab2asanopticalimagingagentinegfrpositivecancers AT elsayedayman evaluationofnimotuzumabfab2asanopticalimagingagentinegfrpositivecancers AT jettkimberlya evaluationofnimotuzumabfab2asanopticalimagingagentinegfrpositivecancers AT casacoangel evaluationofnimotuzumabfab2asanopticalimagingagentinegfrpositivecancers AT fongehumphrey evaluationofnimotuzumabfab2asanopticalimagingagentinegfrpositivecancers AT geyercronald evaluationofnimotuzumabfab2asanopticalimagingagentinegfrpositivecancers |